Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-11-19

AUTHORS

Omar Sheikh, Toshifumi Yokota

ABSTRACT

Duchenne muscular dystrophy (DMD) afflicts 1 in 5000 newborn males, leading to progressive muscle weakening and the loss of ambulation between the ages of 8 and 12. Typically, DMD patients pass away from heart failure or respiratory failure. Currently, there is no cure, though exon-skipping therapy including eteplirsen (brand name Exondys 51), a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene, is considered especially promising. Applicable to approximately 14% of DMD patients, a phosphorodiamidate morpholino oligomer (PMO) antisense oligonucleotide eteplirsen received accelerated approval by the US Food and Drug Administration (FDA) in 2016. Throughout clinical trials, eteplirsen has been well tolerated by patients with no serious drug-related adverse events. The most common events observed are balance disorder, vomiting, and skin rash. Despite its safety and promise of functional benefits, eteplirsen remains controversial due to its low production of dystrophin. In addition, unmodified PMOs have limited efficacy in the heart. To address these concerns of efficacy, eteplirsen has been conjugated to a proprietary cell-penetrating peptide; the conjugate is called SRP-5051. Compared to eteplirsen, SRP-5051 aims to better prompt exon-skipping and dystrophin production but may have greater toxicity concerns. This paper reviews and discusses the available information on the efficacy, safety, and tolerability data of eteplirsen and SRP-5051 from preclinical and clinical trials. Issues faced by eteplirsen and SRP-5051, including efficacy and safety, are identified. Lastly, the current state of eteplirsen and exon-skipping therapy in general as a strategy for the treatment of DMD are discussed. More... »

PAGES

1-9

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00204-021-03184-z

DOI

http://dx.doi.org/10.1007/s00204-021-03184-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1142692599

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34797383


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Exons", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infant, Newborn", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Morpholinos", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Muscular Dystrophy, Duchenne", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligonucleotides, Antisense", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medical Genetics, University of Alberta Faculty of Medicine and Dentistry, T6G 2R3, Edmonton, Canada", 
          "id": "http://www.grid.ac/institutes/grid.17089.37", 
          "name": [
            "Department of Medical Genetics, University of Alberta Faculty of Medicine and Dentistry, T6G 2R3, Edmonton, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sheikh", 
        "givenName": "Omar", 
        "id": "sg:person.015122562227.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015122562227.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Genetics, University of Alberta Faculty of Medicine and Dentistry, T6G 2R3, Edmonton, Canada", 
          "id": "http://www.grid.ac/institutes/grid.17089.37", 
          "name": [
            "Department of Medical Genetics, University of Alberta Faculty of Medicine and Dentistry, T6G 2R3, Edmonton, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yokota", 
        "givenName": "Toshifumi", 
        "id": "sg:person.0755610603.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755610603.48"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nm1345", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016092099", 
          "https://doi.org/10.1038/nm1345"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-020-01267-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1124648968", 
          "https://doi.org/10.1007/s40265-020-01267-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep08986", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046500678", 
          "https://doi.org/10.1038/srep08986"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ejhg.2012.301", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049144250", 
          "https://doi.org/10.1038/ejhg.2012.301"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00431-018-3272-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1109991801", 
          "https://doi.org/10.1007/s00431-018-3272-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.gt.3302800", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005023644", 
          "https://doi.org/10.1038/sj.gt.3302800"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-021-01512-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1137257072", 
          "https://doi.org/10.1007/s40265-021-01512-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41434-020-0156-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1128093431", 
          "https://doi.org/10.1038/s41434-020-0156-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-11-19", 
    "datePublishedReg": "2021-11-19", 
    "description": "Duchenne muscular dystrophy (DMD) afflicts 1 in 5000 newborn males, leading to progressive muscle weakening and the loss of ambulation between the ages of 8 and 12. Typically, DMD patients pass away from heart failure or respiratory failure. Currently, there is no cure, though exon-skipping therapy including eteplirsen (brand name Exondys 51), a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene, is considered especially promising. Applicable to approximately 14% of DMD patients, a phosphorodiamidate morpholino oligomer (PMO) antisense oligonucleotide eteplirsen received accelerated approval by the US Food and Drug Administration (FDA) in 2016. Throughout clinical trials, eteplirsen has been well tolerated by patients with no serious drug-related adverse events. The most common events observed are balance disorder, vomiting, and skin rash. Despite its safety and promise of functional benefits, eteplirsen remains controversial due to its low production of dystrophin. In addition, unmodified PMOs have limited efficacy in the heart. To address these concerns of efficacy, eteplirsen has been conjugated to a proprietary cell-penetrating peptide; the conjugate is called SRP-5051. Compared to eteplirsen, SRP-5051 aims to better prompt exon-skipping and dystrophin production but may have greater toxicity concerns. This paper reviews and discusses the available information on the efficacy, safety, and tolerability data of eteplirsen and SRP-5051 from preclinical and clinical trials. Issues faced by eteplirsen and SRP-5051, including efficacy and safety, are identified. Lastly, the current state of eteplirsen and exon-skipping therapy in general as a strategy for the treatment of DMD are discussed.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00204-021-03184-z", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1019669", 
        "issn": [
          "0340-5761", 
          "1432-0738"
        ], 
        "name": "Archives of Toxicology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "96"
      }
    ], 
    "keywords": [
      "Duchenne muscular dystrophy", 
      "clinical trials", 
      "DMD patients", 
      "serious drug-related adverse events", 
      "drug-related adverse events", 
      "concerns of efficacy", 
      "treatment of DMD", 
      "loss of ambulation", 
      "exon-skipping therapy", 
      "respiratory failure", 
      "tolerability data", 
      "adverse events", 
      "skin rash", 
      "heart failure", 
      "accelerated approval", 
      "balance disorders", 
      "US Food", 
      "Drug Administration", 
      "muscle weakening", 
      "newborn males", 
      "eteplirsen", 
      "patients", 
      "dystrophin production", 
      "muscular dystrophy", 
      "functional benefits", 
      "efficacy", 
      "common event", 
      "therapy", 
      "antisense oligonucleotide", 
      "trials", 
      "safety", 
      "toxicity concerns", 
      "SRP", 
      "dystrophin gene", 
      "vomiting", 
      "rash", 
      "ambulation", 
      "failure", 
      "administration", 
      "dystrophy", 
      "cell-penetrating peptides", 
      "pharmacology", 
      "disorders", 
      "cure", 
      "age", 
      "treatment", 
      "heart", 
      "males", 
      "approval", 
      "low production", 
      "dystrophin", 
      "events", 
      "toxicology", 
      "review", 
      "peptides", 
      "conjugates", 
      "available information", 
      "food", 
      "concern", 
      "genes", 
      "update", 
      "benefits", 
      "loss", 
      "production", 
      "promise", 
      "current state", 
      "data", 
      "addition", 
      "strategies", 
      "exons", 
      "paper reviews", 
      "oligonucleotide", 
      "information", 
      "issues", 
      "PMO", 
      "state", 
      "weakening"
    ], 
    "name": "Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update", 
    "pagination": "1-9", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1142692599"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00204-021-03184-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34797383"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00204-021-03184-z", 
      "https://app.dimensions.ai/details/publication/pub.1142692599"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-10T10:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_900.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00204-021-03184-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00204-021-03184-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00204-021-03184-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00204-021-03184-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00204-021-03184-z'


 

This table displays all metadata directly associated to this object as RDF triples.

210 TRIPLES      22 PREDICATES      119 URIs      103 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00204-021-03184-z schema:about N2383727545fe40f1989862efbfb10330
2 N37692dc4f0634f838387afde9d8a1117
3 N671b23e43bc040a294fd38da5a2bee8a
4 Na985b6d6c18448b3b3e14d3ac3e99034
5 Nae9af2fb2e774c3e958c1ac109e47aeb
6 Nc361124c350c48afad88663630b95eb1
7 Nf2c6e0e52fe04817bcb11998999f662a
8 Nf34df4f3b2354381a598ff6af0865770
9 anzsrc-for:11
10 anzsrc-for:1115
11 schema:author N644a5a00f5f84fa2b885bfb37fc34fdf
12 schema:citation sg:pub.10.1007/s00431-018-3272-1
13 sg:pub.10.1007/s40265-020-01267-2
14 sg:pub.10.1007/s40265-021-01512-2
15 sg:pub.10.1038/ejhg.2012.301
16 sg:pub.10.1038/nm1345
17 sg:pub.10.1038/s41434-020-0156-6
18 sg:pub.10.1038/sj.gt.3302800
19 sg:pub.10.1038/srep08986
20 schema:datePublished 2021-11-19
21 schema:datePublishedReg 2021-11-19
22 schema:description Duchenne muscular dystrophy (DMD) afflicts 1 in 5000 newborn males, leading to progressive muscle weakening and the loss of ambulation between the ages of 8 and 12. Typically, DMD patients pass away from heart failure or respiratory failure. Currently, there is no cure, though exon-skipping therapy including eteplirsen (brand name Exondys 51), a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene, is considered especially promising. Applicable to approximately 14% of DMD patients, a phosphorodiamidate morpholino oligomer (PMO) antisense oligonucleotide eteplirsen received accelerated approval by the US Food and Drug Administration (FDA) in 2016. Throughout clinical trials, eteplirsen has been well tolerated by patients with no serious drug-related adverse events. The most common events observed are balance disorder, vomiting, and skin rash. Despite its safety and promise of functional benefits, eteplirsen remains controversial due to its low production of dystrophin. In addition, unmodified PMOs have limited efficacy in the heart. To address these concerns of efficacy, eteplirsen has been conjugated to a proprietary cell-penetrating peptide; the conjugate is called SRP-5051. Compared to eteplirsen, SRP-5051 aims to better prompt exon-skipping and dystrophin production but may have greater toxicity concerns. This paper reviews and discusses the available information on the efficacy, safety, and tolerability data of eteplirsen and SRP-5051 from preclinical and clinical trials. Issues faced by eteplirsen and SRP-5051, including efficacy and safety, are identified. Lastly, the current state of eteplirsen and exon-skipping therapy in general as a strategy for the treatment of DMD are discussed.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree true
26 schema:isPartOf N02c49b9959724a7a9c0c0af3929e591e
27 Na5375ff6d5a24ecbabd9de3c1213fc97
28 sg:journal.1019669
29 schema:keywords DMD patients
30 Drug Administration
31 Duchenne muscular dystrophy
32 PMO
33 SRP
34 US Food
35 accelerated approval
36 addition
37 administration
38 adverse events
39 age
40 ambulation
41 antisense oligonucleotide
42 approval
43 available information
44 balance disorders
45 benefits
46 cell-penetrating peptides
47 clinical trials
48 common event
49 concern
50 concerns of efficacy
51 conjugates
52 cure
53 current state
54 data
55 disorders
56 drug-related adverse events
57 dystrophin
58 dystrophin gene
59 dystrophin production
60 dystrophy
61 efficacy
62 eteplirsen
63 events
64 exon-skipping therapy
65 exons
66 failure
67 food
68 functional benefits
69 genes
70 heart
71 heart failure
72 information
73 issues
74 loss
75 loss of ambulation
76 low production
77 males
78 muscle weakening
79 muscular dystrophy
80 newborn males
81 oligonucleotide
82 paper reviews
83 patients
84 peptides
85 pharmacology
86 production
87 promise
88 rash
89 respiratory failure
90 review
91 safety
92 serious drug-related adverse events
93 skin rash
94 state
95 strategies
96 therapy
97 tolerability data
98 toxicity concerns
99 toxicology
100 treatment
101 treatment of DMD
102 trials
103 update
104 vomiting
105 weakening
106 schema:name Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update
107 schema:pagination 1-9
108 schema:productId N02474b3f9bc54eb1b8e861448ba5f256
109 N23d337a16d4643bbb70dc9fd35807a37
110 N906c693b97414ad7961d6dcc734fa3c9
111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1142692599
112 https://doi.org/10.1007/s00204-021-03184-z
113 schema:sdDatePublished 2022-05-10T10:28
114 schema:sdLicense https://scigraph.springernature.com/explorer/license/
115 schema:sdPublisher Ndb0e6419074441599201f13b38c27ad5
116 schema:url https://doi.org/10.1007/s00204-021-03184-z
117 sgo:license sg:explorer/license/
118 sgo:sdDataset articles
119 rdf:type schema:ScholarlyArticle
120 N02474b3f9bc54eb1b8e861448ba5f256 schema:name doi
121 schema:value 10.1007/s00204-021-03184-z
122 rdf:type schema:PropertyValue
123 N02c49b9959724a7a9c0c0af3929e591e schema:volumeNumber 96
124 rdf:type schema:PublicationVolume
125 N2383727545fe40f1989862efbfb10330 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Male
127 rdf:type schema:DefinedTerm
128 N23d337a16d4643bbb70dc9fd35807a37 schema:name pubmed_id
129 schema:value 34797383
130 rdf:type schema:PropertyValue
131 N37692dc4f0634f838387afde9d8a1117 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Child
133 rdf:type schema:DefinedTerm
134 N644a5a00f5f84fa2b885bfb37fc34fdf rdf:first sg:person.015122562227.63
135 rdf:rest N70b567fedba0448fb7b0ce877c65f736
136 N671b23e43bc040a294fd38da5a2bee8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Morpholinos
138 rdf:type schema:DefinedTerm
139 N70b567fedba0448fb7b0ce877c65f736 rdf:first sg:person.0755610603.48
140 rdf:rest rdf:nil
141 N906c693b97414ad7961d6dcc734fa3c9 schema:name dimensions_id
142 schema:value pub.1142692599
143 rdf:type schema:PropertyValue
144 Na5375ff6d5a24ecbabd9de3c1213fc97 schema:issueNumber 1
145 rdf:type schema:PublicationIssue
146 Na985b6d6c18448b3b3e14d3ac3e99034 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Humans
148 rdf:type schema:DefinedTerm
149 Nae9af2fb2e774c3e958c1ac109e47aeb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Oligonucleotides, Antisense
151 rdf:type schema:DefinedTerm
152 Nc361124c350c48afad88663630b95eb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Infant, Newborn
154 rdf:type schema:DefinedTerm
155 Ndb0e6419074441599201f13b38c27ad5 schema:name Springer Nature - SN SciGraph project
156 rdf:type schema:Organization
157 Nf2c6e0e52fe04817bcb11998999f662a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Exons
159 rdf:type schema:DefinedTerm
160 Nf34df4f3b2354381a598ff6af0865770 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Muscular Dystrophy, Duchenne
162 rdf:type schema:DefinedTerm
163 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
164 schema:name Medical and Health Sciences
165 rdf:type schema:DefinedTerm
166 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
167 schema:name Pharmacology and Pharmaceutical Sciences
168 rdf:type schema:DefinedTerm
169 sg:journal.1019669 schema:issn 0340-5761
170 1432-0738
171 schema:name Archives of Toxicology
172 schema:publisher Springer Nature
173 rdf:type schema:Periodical
174 sg:person.015122562227.63 schema:affiliation grid-institutes:grid.17089.37
175 schema:familyName Sheikh
176 schema:givenName Omar
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015122562227.63
178 rdf:type schema:Person
179 sg:person.0755610603.48 schema:affiliation grid-institutes:grid.17089.37
180 schema:familyName Yokota
181 schema:givenName Toshifumi
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755610603.48
183 rdf:type schema:Person
184 sg:pub.10.1007/s00431-018-3272-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109991801
185 https://doi.org/10.1007/s00431-018-3272-1
186 rdf:type schema:CreativeWork
187 sg:pub.10.1007/s40265-020-01267-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1124648968
188 https://doi.org/10.1007/s40265-020-01267-2
189 rdf:type schema:CreativeWork
190 sg:pub.10.1007/s40265-021-01512-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1137257072
191 https://doi.org/10.1007/s40265-021-01512-2
192 rdf:type schema:CreativeWork
193 sg:pub.10.1038/ejhg.2012.301 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049144250
194 https://doi.org/10.1038/ejhg.2012.301
195 rdf:type schema:CreativeWork
196 sg:pub.10.1038/nm1345 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016092099
197 https://doi.org/10.1038/nm1345
198 rdf:type schema:CreativeWork
199 sg:pub.10.1038/s41434-020-0156-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128093431
200 https://doi.org/10.1038/s41434-020-0156-6
201 rdf:type schema:CreativeWork
202 sg:pub.10.1038/sj.gt.3302800 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005023644
203 https://doi.org/10.1038/sj.gt.3302800
204 rdf:type schema:CreativeWork
205 sg:pub.10.1038/srep08986 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046500678
206 https://doi.org/10.1038/srep08986
207 rdf:type schema:CreativeWork
208 grid-institutes:grid.17089.37 schema:alternateName Department of Medical Genetics, University of Alberta Faculty of Medicine and Dentistry, T6G 2R3, Edmonton, Canada
209 schema:name Department of Medical Genetics, University of Alberta Faculty of Medicine and Dentistry, T6G 2R3, Edmonton, Canada
210 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...